Expand Energy Corporation Common Stock vs Novo Nordisk A/S — how do they compare? Expand Energy Corporation Common Stock trades at $91.47 (market cap $21.38B), while Novo Nordisk A/S trades at $38.61 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 7.9× Expand Energy Corporation Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Expand Energy Corporation Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| EXE | NVO | |
|---|---|---|
Market Cap | $21.38B | $169.08B |
Volume | 3,544,570 | 9,259,152 |
Sector | Energy | Health |
52-Week High | $122.89 | $63.98 |
52-Week Low | $84.09 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $24.45B | $183.28B |
Dividend Yield | 2.49% | 4.72% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Expand Energy Corporation is a US natural gas producer formed from the 2024 merger of Chesapeake Energy and Southwestern Energy, developing gas assets concentrated in the Appalachia and Haynesville basins.
Read more on EXE →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →